Last updated: September 5, 2026
Synarel is Pfizer’s branded nafarelin acetate nasal spray, a gonadotropin-releasing hormone agonist approved in the United States for endometriosis and central precocious puberty. Its commercial profile is mature and declining: original regulatory and exclusivity protections expired years ago, no material current Orange Book patent barrier is evident, and the product competes with injectable GnRH agonists, newer oral GnRH antagonists, and alternative pediatric endocrine therapies. Pfizer does not separately report Synarel revenue, so product-level financial performance cannot be measured from public filings. [1-4]
What is Synarel and how is it used?
Synarel contains nafarelin acetate at a concentration of 2 mg/mL. It is administered intranasally and suppresses pituitary gonadotropin secretion after an initial stimulation phase.
The FDA-approved uses are:
| Indication |
Patient group |
Principal commercial alternative |
| Endometriosis |
Adults with symptomatic disease |
Oral GnRH antagonists, injectable GnRH agonists, hormonal contraceptives, surgery |
| Central precocious puberty |
Pediatric patients |
Leuprolide injections, histrelin implant, triptorelin, deslorelin in selected markets |
The product’s nasal delivery system differentiates Synarel from depot injections and implants, but the device also creates adherence and administration disadvantages. Patients must use the spray on a recurring schedule, and nasal congestion or incorrect administration can affect exposure. The FDA label identifies a treatment duration limit for endometriosis because of hypoestrogenic effects and bone mineral density concerns. [1]
When did Synarel lose exclusivity?
Synarel’s primary pharmaceutical exclusivity expired long before the current market period. The product was approved by the FDA under NDA 019886 in 1989. Any original composition, formulation, or use patents associated with the product would have reached their ordinary term years ago, subject to patent-term adjustments and extensions. [2]
Synarel exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| FDA approval of Synarel nasal spray |
1989 |
U.S. commercial launch |
| Original product and use patent period |
1990s to early 2000s |
Protected branded pricing and market access |
| Conventional small-molecule exclusivity period |
Expired decades ago |
No current regulatory exclusivity protection |
| Current market position |
Mature product |
Competition based on supply, prescribing habits, and clinical preference |
Synarel does not have biologic exclusivity. It is a synthetic peptide-related small-molecule drug product regulated through the conventional NDA framework. Biosimilar competition is therefore not relevant. Any future competitor would generally enter through an abbreviated new drug application or another applicable small-molecule pathway, rather than through the biosimilar framework.
What patents protect Synarel?
Synarel’s active patent position is weak relative to newer specialty pharmaceuticals. The original active ingredient and early clinical uses are no longer commercially protected by enforceable exclusivity periods.
Orange Book status
The FDA Orange Book is the principal U.S. source for listed patents and regulatory exclusivity associated with approved drug products. Synarel’s commercial value is not supported by a current, high-value Orange Book patent estate. The product’s main barriers are practical rather than legal:
- limited supplier and manufacturing capacity;
- specialized nasal spray development;
- regulatory requirements for demonstrating pharmaceutical equivalence;
- small and fragmented patient populations;
- limited commercial incentive for generic manufacturers;
- physician and patient familiarity with incumbent products.
The absence of a meaningful patent barrier does not guarantee generic entry. A low-volume product can remain branded when the expected return from generic development is insufficient.
Formulation and delivery-system protection
Synarel’s nasal formulation historically provided more commercial differentiation than the nafarelin molecule itself. A competing product would need to match the active ingredient, concentration, delivery performance, container-closure system, stability profile, and dosing instructions.
Those technical requirements can delay entry, but they do not create durable exclusivity where the relevant formulation claims have expired or are not listed as active Orange Book patents. The nasal route also limits substitution economics because a generic manufacturer must establish equivalent spray performance, not merely reproduce a tablet or injectable dosage form.
Does Synarel have FDA exclusivity or Orange Book protection?
Synarel has no meaningful remaining FDA exclusivity period. Its regulatory value comes from the existence of an approved NDA and an established clinical record, not from current market exclusivity.
The FDA label identifies Synarel as a prescription nasal spray approved for two established indications. The product is not a new chemical entity, orphan product, or biologic with an active statutory exclusivity period. [1, 2]
Paragraph IV challenge risk
A Paragraph IV certification would be relevant only if a listed patent remained in force. Synarel’s old patent position provides little apparent basis for a commercially significant Paragraph IV dispute.
The more important question is whether an applicant would pursue a generic at all. The market is relatively small, the product has specialized administration requirements, and alternative treatments are well established. These factors can reduce the attractiveness of an ANDA even where patent barriers are weak.
No major, publicly reported Paragraph IV litigation or settlement agreement has materially reshaped the Synarel market in recent years.
How strong is the Synarel patent estate?
Synarel’s patent estate is commercially weak.
| Patent-estate factor |
Assessment |
| Active composition-of-matter protection |
None expected |
| Active regulatory exclusivity |
None |
| Active Orange Book barrier |
No material current barrier identified |
| Formulation protection |
Historical, with limited current force |
| Method-of-use protection |
Historical and commercially expired |
| Manufacturing know-how |
Potentially relevant but not publicly quantified |
| Litigation leverage |
Low |
| Generic entry protection |
Low legal protection, moderate practical friction |
The product’s residual defensibility depends on operational execution. Pfizer or another supplier can retain share through reliable supply, physician familiarity, and the absence of a well-funded generic challenger. Those factors are weaker protections than an enforceable patent.
What is the competitive landscape for Synarel?
Synarel competes in two different therapeutic markets.
Endometriosis market
For endometriosis, Synarel competes with:
- leuprolide depot injections, including Lupron Depot;
- elagolix, marketed as Orilissa;
- relugolix combination therapy, marketed as Myfembree;
- elagolix combination therapy, marketed as Oriahnn for uterine fibroids rather than endometriosis;
- hormonal contraceptives and progestins;
- surgical treatment.
Oral GnRH antagonists have changed the treatment sequence by providing rapid suppression without the initial flare associated with GnRH agonists. They also offer more convenient administration than a nasal spray or injection. Their branded patent estates and pricing have been materially stronger than Synarel’s.
Central precocious puberty market
For central precocious puberty, Synarel competes with:
- leuprolide depot products;
- triptorelin depot products;
- histrelin implants, including Supprelin LA;
- newer long-acting pediatric GnRH agonist formulations.
The pediatric market favors sustained-release injections and implants because they reduce daily administration burden. Synarel’s nasal route can remain useful where families prefer an at-home option, but its convenience advantage is less clear when compared with once-monthly, three-month, six-month, or annual therapies.
What is Synarel’s FDA regulatory status?
Synarel remains associated with an FDA-approved NDA and established labeling for endometriosis and central precocious puberty. Its regulatory status should be separated from commercial availability.
A drug can retain an approved NDA while experiencing limited distribution, supply disruption, or discontinuation in a particular market. Pfizer’s public product and regulatory disclosures do not provide a standalone revenue line for Synarel. FDA product records and labeling establish the approved product profile, but they do not establish current sales volume. [1, 2]
The principal regulatory risks are standard for a mature nasal product:
- manufacturing consistency;
- device and spray-performance controls;
- supply continuity;
- labeling compliance;
- pediatric dosing and monitoring;
- bone mineral density and hypoestrogenic adverse effects in endometriosis treatment.
Is Synarel discontinued or in shortage?
Synarel’s availability has been subject to market-specific and time-specific supply conditions. Public regulatory databases should be used to distinguish among:
- permanent commercial discontinuation;
- temporary supply interruption;
- discontinuation of a particular package or presentation;
- continued FDA approval with limited distribution.
The FDA’s drug-supply and product databases do not provide a reliable standalone measure of sales or long-term commercial commitment. A supply interruption would have an immediate effect because patients and physicians have relatively few intranasal nafarelin substitutes, but the broader therapeutic markets have multiple alternatives. [3]
What is Synarel’s financial trajectory?
Pfizer does not separately disclose Synarel net sales, gross margin, or operating income in its annual reports. Synarel is included, if at all, within broader product or portfolio categories that do not permit a product-specific revenue calculation. [4]
Commercial trajectory
| Period |
Financial interpretation |
| 1990s |
Protected branded specialty product with limited but defensible demand |
| 2000s |
Mature brand after loss of primary exclusivity |
| 2010s |
Declining strategic importance as injectable and newer oral therapies expanded |
| 2020s |
Low-visibility mature product with no separately disclosed revenue |
| Forward outlook |
Stable-to-declining demand, with upside limited to supply recovery or niche retention |
Synarel’s revenue trajectory is likely shaped by four forces:
- Therapeutic substitution. Oral GnRH antagonists and long-acting depot products reduce reliance on daily nasal administration.
- Generic economics. Patent expiry creates theoretical entry risk, but the addressable market may be too small to support multiple competitors.
- Supply sensitivity. A single-source or limited-source market can produce abrupt revenue changes unrelated to underlying demand.
- Portfolio deprioritization. A mature product without current exclusivity generates limited strategic value for a large pharmaceutical company unless it remains profitable or fills a supply-critical niche.
No reliable public source supports a precise Synarel revenue estimate. Any numerical forecast would be speculative without audited product-level sales data.
Which companies are challenging Synarel?
No major publicly reported company has emerged as a high-profile litigation challenger to Synarel. Competitive pressure is more likely to come from therapeutic substitutes than from direct nafarelin generic entry.
The relevant competitor groups are:
| Competitor type |
Examples |
Risk to Synarel |
| GnRH agonist injections |
Lupron Depot, Fensolvi, Triptodur |
High in pediatric use and specialist practice |
| GnRH antagonist tablets |
Orilissa, Myfembree |
High in endometriosis treatment |
| GnRH implants |
Supprelin LA |
Moderate to high in central precocious puberty |
| Generic nafarelin nasal spray |
Potential ANDA entrants |
Legally feasible, commercially uncertain |
| Surgical and hormonal treatments |
Laparoscopic surgery, progestins, contraceptives |
Persistent substitution risk |
What litigation and settlement agreements affect Synarel?
No material current patent litigation or publicly reported settlement agreement appears to drive Synarel’s commercial outlook. The product’s central risks are commercial and operational rather than litigation-based.
A future generic applicant could still face ordinary FDA review, bioequivalence questions, device-performance requirements, and product-liability exposure. Those issues would affect launch timing without recreating the exclusivity protection that Synarel once had.
How does Synarel compare with newer endometriosis drugs?
| Attribute |
Synarel |
Oral GnRH antagonists |
| Active mechanism |
GnRH agonist |
GnRH antagonist |
| Administration |
Intranasal, recurring dosing |
Oral |
| Initial hormonal flare |
Possible |
Avoided |
| Market maturity |
Established, old product |
Newer branded products |
| Patent protection |
Weak or expired |
Generally stronger, product-specific estates |
| Commercial pricing power |
Limited |
Higher branded pricing |
| Adherence burden |
Nasal administration |
Tablet administration |
| Long-term growth |
Low |
Higher but subject to payer and safety constraints |
Synarel retains clinical familiarity and may be useful for patients who cannot use other options. Its commercial disadvantage is that its delivery system does not compensate for its old mechanism, weak patent position, and competition from products with greater dosing convenience or newer IP.
What generic launch scenarios exist for Synarel?
Three scenarios are commercially plausible:
Scenario 1: No generic launch
This is the most defensible base case if the market remains too small or supply economics remain unattractive. Pfizer or a successor supplier could retain most demand despite the absence of patent protection.
Scenario 2: Single generic entrant
A single ANDA entrant could capture price-sensitive prescriptions while the brand retains specialist and continuity-of-care demand. The effect would depend on payer substitution and supply reliability.
Scenario 3: Multiple generic entrants
Multiple entrants would create rapid price compression and could destabilize supply if the total market cannot support several manufacturers. This scenario is legally possible but commercially less likely than in high-volume oral solid products.
What is the geographic coverage of Synarel?
Synarel’s commercial significance is concentrated in markets where nafarelin has regulatory approval, reimbursement, and an established supplier. Patent expiry is jurisdiction-specific, but the product’s original protection is generally exhausted in major markets.
The principal geographic variables are:
- local approval status;
- reimbursement for endometriosis and pediatric endocrine use;
- availability of injectable and implant alternatives;
- manufacturer distribution decisions;
- local generic substitution rules;
- country-specific supply conditions.
The United States remains the most important reference market because of the FDA-approved NDA and Orange Book framework. International sales, where present, are not separately disclosed by Pfizer.
Key Takeaways
- Synarel is nafarelin acetate nasal spray, approved for endometriosis and central precocious puberty.
- FDA approval dates to 1989, and original exclusivity has expired.
- No material current Orange Book patent barrier is evident.
- Biosimilar risk does not apply because Synarel is not a biologic.
- The main competitive threats are newer oral GnRH antagonists, depot injections, and histrelin implants.
- Pfizer does not disclose Synarel revenue separately.
- The financial trajectory is mature to declining, with performance driven by supply, substitution, and portfolio strategy.
- Generic entry is legally feasible but commercially uncertain because the addressable market is specialized and relatively small.
- No major current Paragraph IV litigation or settlement agreement is publicly reported as a central Synarel market driver.
FAQs
Is Synarel still commercially available in the United States?
Availability depends on current manufacturer distribution and supply conditions. FDA approval and commercial availability are separate issues, and public regulatory records do not establish continuous retail supply.
Is there a generic version of Synarel?
The absence of a widely established generic does not reflect active patent exclusivity. It more likely reflects limited market size, technical nasal-spray requirements, and uncertain generic economics.
Is nafarelin the same as leuprolide?
No. Both are GnRH agonists, but nafarelin is delivered intranasally while leuprolide is generally administered by injection or depot formulation. Their dosing schedules and product-specific labels differ.
Can Synarel patents block a new nasal nafarelin product?
A current patent would need to be identified and enforceable in the relevant jurisdiction. Synarel’s historic exclusivity is not sufficient by itself to block a new product.
What is the most important investment risk for Synarel?
The principal risk is demand erosion from newer therapies and long-acting products, combined with limited visibility into product-level revenue and possible supply volatility.
References
- U.S. Food and Drug Administration. (n.d.). Synarel (nafarelin acetate) nasal solution prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Synarel, NDA 019886.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations; FDA drug shortages and availability databases.
- Pfizer Inc. (2024). 2023 annual report and Form 10-K. New York, NY: Pfizer Inc.
